Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund’s Investor Class APFDX returned -3.67%, Advisor Class APDDX posted a return of -3.65%, and Institutional Class APHDX returned -3.62%, compared to a -1.71% return for the MSCI All Country World Small Mid Index. Investor sentiment as 2025 approached was positive. In 2024, US equities once more surpassed their global counterparts, raising expectations that the incoming Republican administration would bolster the idea of US exceptionalism. However, the first quarter surprised everyone. In addition, please check the fund’s top five holdings to know its best picks in 2025.
In its first-quarter 2025 investor letter, Artisan Global Discovery Fund highlighted stocks such as PROCEPT BioRobotics Corporation (NASDAQ:PRCT). PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a surgical robotics company. The one-month return of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) was 5.32%, and its shares lost 3.18% of their value over the last 52 weeks. On June 12, 2025, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) stock closed at $61.16 per share, with a market capitalization of $3.384 billion.
Artisan Global Discovery Fund stated the following regarding PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in its Q1 2025 investor letter:
“During the quarter, we initiated new GardenSM positions in Aris Water Solution and BioRobotics Corporation (NASDAQ:PRCT). PROCEPT BioRobotics is a surgical robotic company that develops, markets and sells robotic system to treat benign prostatic hyperplasia (BPH). The company has successfully placed robotic systems globally and has developed a significant (and growing) body of clinical evidence and peer-reviewed publications. Meanwhile, most of its target population has access to the procedure due to broadening insurance coverage. The company only has about 10% market share in BPH, but it has taken market share from competitors as its robotic systems provide greater efficacy, safety advantages, and faster and more predictable procedures. Meanwhile, the technology has the potential to be utilized across other procedures. The company will soon release trial results for prostate cancer, which would meaningfully expand its market opportunity.”
A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 27 hedge fund portfolios held PROCEPT BioRobotics Corporation (NASDAQ:PRCT) at the end of the first quarter, which was 27 in the previous quarter. In Q1 2025, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) reported revenue of $69.2 million, up 55% compared to the first quarter of 2024. While we acknowledge the potential of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains.
In another article, we covered PROCEPT BioRobotics Corporation (NASDAQ:PRCT) and shared the list of best robotics stocks to buy according to billionaires.. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of PRCT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
